Results 81 to 90 of about 108,133 (341)

Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning [PDF]

, 2016
This work was supported by the British Heart Foundation (Ref: RG/14/4/30736), Medical Research Council (MR/N02589X/1) and The Wellcome Trust (Ref: 200893/Z/16/Z). A.V.G. is a Wellcome Trust Senior Research Fellow. S.M.
Aleksander Mrochek, Alexander V. Gourine, Ana Gutierrez del Arroyo, Andrey Gourine, Barragán, Gareth L. Ackland, Gourine, Göke, Jenifer Sanchez, John Pernow, Marina V. Basalay, Per-Ove Sjoquist, Svetlana Mastitskaya, Uitterdijk   +13 more
core   +2 more sources

Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration

Advanced Science, EarlyView.
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély, István Narozsny, Levente Szarka, Daniel V. Veres, Peter Csermely, Dávid Keresztes   +5 more
wiley   +1 more source

Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology

Journal of Diabetology
A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj   +1 more source

Central mechanisms mediating the hypophagic effects of oleoylethanolamide and N-acylphosphatidylethanolamines: different lipid signals? [PDF]

, 2015
The spread of "obesity epidemic" and the poor efficacy of many anti-obesity therapies in the long-term highlight the need to develop novel efficacious therapy. This necessity stimulates a large research effort to find novel mechanisms controlling feeding
Gaetani, Silvana, Passani, Maria B., Provensi, Gustavo, Romano, Adele, Tempesta, Bianca   +4 more
core   +2 more sources

Mitochondrial Transplantation as a Therapeutic Strategy for Inherited Mitochondrial Diseases

Advanced Science, EarlyView.
Mitochondrial transplantation (MTx) offers a promising therapeutic avenue for mitochondrial diseases. This review comprehensively evaluates MTx, differentiating its feasibility for mtDNA‐ and nDNA‐based disorders. It examines its potential for genetic correction, alongside inherent limitations, technical challenges, and crucial ethical considerations ...
Parmeshar Singh, Amir Tahavvori, Cyrus E. Kuschner, Blanca B. Espin, Jacob Kazmi, Sofhia V. Ramos, Tai Yin, Kei Hayashida, Kanako Ito‐Hagiwara, Yusuke Endo, Keitaro Yoshioka, Jun Hagiwara, Avijot Sohi, Alisha Oropallo, Ghania Haddad, Timmy Li, Lance B. Becker, Junhwan Kim   +17 more
wiley   +1 more source

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]

Endocrinology and Metabolism
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen   +2 more
doaj   +1 more source

GLP-1 Agonists in Type 1 Diabetes Mellitus: A Review of the Literature [PDF]

, 2016
Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). Data Sources: A search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the search terms glucagon-like ...
Janzen, Kristin M., Nisly, Sarah A., Steuber, Taylor D.   +2 more
core   +2 more sources

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Diffuse Podocytopathy Associated With Semaglutide

Annals of Internal Medicine: Clinical Cases
We present 3 cases of biopsy-proven minimal change disease occurring in close temporal association with semaglutide (glucagon-like peptide 1 receptor agonists) exposure.
Rose Mary Attieh, Grant Kirby, Yang Yihe, Serena Bagnasco, Andrew A. Moses, Mahmoud Abdelaziz, Rimda Wanchoo, Samir Gautam, Astrid Weins, Kenar D. Jhaveri   +9 more
doaj   +1 more source

Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. [PDF]

, 2014
Background: Rodents are incapable of emesis and consequently the emetic potential of glucagon-like peptide-1 receptor (GLP-1R) agonists in studies designed to assess a potential blood glucose lowering action of the compound was missed.
A Amato, A Flint, A Rotondo, A Vella, A Wettergren, AD Farmer, AH Barnett, AM Holmes, B Kreymann, BD Kiernan, BP Bullock, C Tourrel, CA Richards, Chi-Kong Yeung, CM Edwards, CR Abbott, David TW Yew, DD De Leon, Ge Lin, GJ Sanger, GM Holmes, GR Morrow, I Billig, I Doweck, INC Lawes, J Kim, JA Kim, JL Iltz, JL Lachey, JM Egan, John A Rudd, JP Gutzwiller, JP Gutzwiller, JP Gutzwiller, K Venkova, KE Mayo, KP Kinzig, L Van Bloemendaal, L Zheng, LL Baggio, LT LaCount, M Reardon, MM Combettes, N Imeryuz, N Percie Du Sert, N Percie du Sert, N Percie Du Sert, NA Gupta, Nathalie Percie Du Sert, NH Greig, P Bhandari, Paul LR Andrews, PJ Gianaros, PJ Shughrue, PL Andrews, R Goke, R Goke, R Shirazi, RM Stern, S Madsbad, SE Ayachi, SE Kanoski, SW Chan, SW Chan, SW Chan, Sze Wa Chan, T Perry, T Tolessa, T Tolessa, V Bucinskaite, Y Wei, Zengbing Lu   +71 more
core   +1 more source